Clinical evaluation of ceftazidime in high risk patients.
Ceftazidime was used in 19 patients at high risk owing to severe impairment of natural defense systems. The therapeutic efficacy and adverse reactions produced by cephalosporin, as evaluated on the basis of the results of clinical investigations and laboratory tests, were regarded as positive.
D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001424:Bacterial Infections / Q000188:drug therapy*; D001663:Bilirubin / Q000097:blood; D001806:Blood Urea Nitrogen; D001831:Body Temperature; D002442:Ceftazidime / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D012306:Risk; D013997:Time Factors
D002442:Ceftazidime; D003404:Creatinine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin